CJC-1295 (Growth Hormone Releasing Hormone Analog)

What Is CJC-1295?

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), the endogenous hypothalamic peptide that stimulates the anterior pituitary gland to produce and secrete growth hormone (GH). It was originally developed by ConjuChem Biotechnologies and has been studied for its ability to increase plasma GH and IGF-1 levels in both animal models and human clinical trials.

CJC-1295 exists in two primary forms:

• CJC-1295 without DAC (also called Modified GRF 1-29): A 29-amino-acid peptide with a short half-life of approximately 30 minutes. Produces a pulsatile GH release that more closely mimics natural physiology.
• CJC-1295 with DAC (Drug Affinity Complex): The same peptide conjugated with a maleimidopropionic acid linker that binds to serum albumin, extending the half-life to 6-8 days. Produces sustained, elevated GH levels.

Key distinction: The no-DAC version is generally preferred in clinical and optimization settings because it preserves the natural pulsatile pattern of GH release, which is considered healthier and less likely to cause side effects than the sustained elevation produced by the DAC variant.

Mechanism of Action

How CJC-1295 Stimulates Growth Hormone

CJC-1295 works by binding to the GHRH receptor (GHRH-R) on somatotroph cells in the anterior pituitary gland. This initiates a signaling cascade:

1. GHRH receptor binding activates adenylyl cyclase via Gs-protein coupling
2. Increased cyclic AMP (cAMP) activates protein kinase A (PKA)
3. PKA activation leads to calcium influx and GH gene transcription
4. Growth hormone is synthesized and released into the bloodstream
5. GH then stimulates hepatic IGF-1 production, which mediates many of GH’s anabolic effects

Why CJC-1295 Is More Effective Than Natural GHRH

Native GHRH (1-44) has a plasma half-life of less than 7 minutes due to rapid enzymatic degradation by dipeptidyl peptidase IV (DPP-IV). CJC-1295 incorporates four amino acid substitutions at positions 2, 8, 15, and 27 that confer resistance to DPP-IV cleavage, dramatically extending its bioactivity.

The DAC Difference

The Drug Affinity Complex allows the peptide to covalently bind to serum albumin after injection. This creates a long-circulating reservoir:

• No DAC: Half-life ~30 minutes. Produces a GH pulse lasting 2-3 hours.
• With DAC: Half-life ~6-8 days. Produces sustained GH elevation for days.

The no-DAC version’s pulsatile action more closely mimics the body’s natural GH secretion pattern (which involves 6-12 pulses per 24 hours, with the largest pulse occurring during deep sleep).

Clinical Research

Human Studies

A key clinical trial published in the Journal of Clinical Endocrinology & Metabolism (2006) examined CJC-1295 DAC in healthy adults aged 21-61:

• Single dose of 60-90mcg/kg increased mean GH levels by 2-10 fold for up to 6 days
• IGF-1 levels increased by 1.5-3 fold and remained elevated for 9-11 days
• No serious adverse events were reported at therapeutic doses
• Pituitary responsiveness was maintained (no evidence of tachyphylaxis during the study period)

Additional research has demonstrated:

• Dose-dependent increases in both GH and IGF-1 with repeated administration
• Preservation of normal GH pulsatility with the no-DAC variant
• Synergistic effects when combined with growth hormone secretagogues (GHS) like Ipamorelin
• Improved body composition metrics in clinical settings

Limitations of Current Research

It is important to note that:

• Most human studies have been short-term (weeks to months)
• Long-term safety data beyond 1-2 years is limited
• Many studies were industry-sponsored
• CJC-1295 has not completed Phase III clinical trials for any indication
• Real-world use often involves protocols not validated in clinical trials

Benefits of CJC-1295

Body Composition

Growth hormone is a powerful regulator of body composition. By increasing GH and IGF-1 levels, CJC-1295 may support:

• Fat loss: GH stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat storage). This effect is particularly pronounced in visceral (abdominal) fat.
• Lean mass preservation: IGF-1 promotes protein synthesis and inhibits protein degradation in skeletal muscle.
• Improved metabolic rate: Elevated GH increases basal metabolic rate by 10-20% in some studies.

Recovery and Repair

• Accelerated recovery from exercise-induced muscle damage
• Enhanced collagen synthesis for connective tissue repair
• Improved bone mineral density with long-term use
• Joint health support through enhanced synovial fluid production

Sleep Quality

One of the earliest and most consistently reported benefits:

• Deeper sleep with more time in slow-wave (stage 3) sleep
• Improved REM sleep architecture
• More restorative sleep with better subjective sleep quality
• Natural GH pulse amplification during the nocturnal GH peak

Skin and Anti-Aging

• Increased skin thickness and elasticity
• Improved collagen production leading to reduced wrinkle depth
• Enhanced wound healing capacity
• Hair and nail growth improvement

Dosing Protocols

CJC-1295 Without DAC (Modified GRF 1-29)

This is the preferred variant for most optimization protocols:

Timing recommendations:

• Primary injection: 30-60 minutes before bed on an empty stomach (amplifies the natural nocturnal GH pulse)
• Secondary injection (if applicable): Upon waking, before eating
• Third injection (if applicable): Post-workout, before eating
• Always on an empty stomach: Food (especially carbohydrates and fats) blunts GH release through insulin and somatostatin elevation

CJC-1295 With DAC

Notes on DAC variant:

• Less precise dosing control due to long half-life
• Sustained GH elevation may carry higher side effect burden
• Weekly injection schedule improves compliance
• Less commonly recommended by hormone optimization physicians compared to no-DAC variant

The CJC-1295 + Ipamorelin Protocol

The most widely used clinical protocol combines CJC-1295 (no DAC) with Ipamorelin:

• CJC-1295 (no DAC): 100mcg
• Ipamorelin: 100-200mcg
• Combined in the same syringe: Yes, these can be mixed
• Frequency: 1-3x daily
• Primary timing: Before bed, fasted

This combination produces a synergistic GH release because CJC-1295 stimulates GH production (via GHRH-R) while Ipamorelin stimulates GH release (via ghrelin receptor/GHS-R). The two pathways are complementary and produce greater GH output than either peptide alone.

Reconstitution and Storage

Preparation

1. Starting material: Lyophilized (freeze-dried) powder, typically 2mg or 5mg per vial
2. Reconstitution solvent: Bacteriostatic water (BAC water) - NOT sterile water or saline
3. Standard reconstitution: Add 2mL BAC water to a 2mg vial (yields 1mg/mL or 100mcg per 0.1mL)
4. Technique: Direct the stream of BAC water along the vial wall; do not spray directly onto the powder. Swirl gently - never shake.

Storage

• Unreconstituted: Stable at room temperature for weeks; refrigerated for months; frozen for years
• Reconstituted: Must be refrigerated (2-8C / 36-46F). Stable for approximately 4-6 weeks
• Never freeze reconstituted peptide (destroys the protein structure)
• Protect from light and excessive heat

Cycling Guidelines

Cycling is essential to prevent receptor desensitization and maintain the pituitary’s ability to respond to GHRH signaling:

Standard Cycling

• On cycle: 8-12 weeks
• Off cycle: 4-6 weeks
• Weekly pattern (no DAC): 5 days on, 2 days off

Extended Protocol

Some physicians recommend:

• Phase 1 (Loading): 12 weeks at standard dose
• Phase 2 (Maintenance): Reduce to bedtime-only dosing for 4-8 weeks
• Phase 3 (Break): 4-6 weeks completely off
• Repeat cycle

Signs You Need to Cycle Off

• Diminishing response (tolerance)
• Increased water retention
• Persistent numbness or tingling
• Elevated fasting blood glucose

Side Effects

Common (usually mild and transient)

• Flushing and warmth at injection site or face (10-20 minutes post-injection)
• Water retention (typically in hands and feet)
• Increased appetite (a GH effect)
• Tingling or numbness in extremities
• Vivid dreams (related to deeper sleep)
• Headache (usually resolves within first week)

Less Common

• Injection site reactions (redness, itching, small lumps)
• Mild joint stiffness (related to water retention)
• Dizziness or lightheadedness shortly after injection
• Increased sweating

Serious (rare, usually dose-related)

• Carpal tunnel-like symptoms (from water retention and tissue swelling)
• Insulin resistance (monitor fasting glucose)
• Potential tumor growth (GH/IGF-1 can stimulate growth of existing tumors)
• Pituitary suppression with excessive use without cycling

Who Should NOT Use CJC-1295

• Individuals with active cancer or a history of cancer
• Pregnant or breastfeeding women
• Individuals with uncontrolled diabetes
• Those with active pituitary disorders (unless under specialist care)
• Children (unless prescribed by a pediatric endocrinologist for specific conditions)
• Individuals with known hypersensitivity to GHRH analogs

Monitoring and Blood Work

If using CJC-1295 under medical supervision, the following should be monitored:

• IGF-1 levels (target: upper third of age-appropriate range)
• Fasting blood glucose and HbA1c (to detect insulin resistance)
• Fasting insulin levels
• Complete metabolic panel
• Thyroid function (TSH, free T3, free T4)
• Prolactin (CJC-1295 should not significantly elevate prolactin, unlike some GHRPs)
• PSA in males over 40

Legal Status and Sourcing

CJC-1295 is currently:

• Not FDA-approved for any human medical use
• Available as a research chemical from peptide synthesis companies
• Prescribed off-label by some licensed physicians through compounding pharmacies
• Legal to possess in most jurisdictions when obtained for research purposes
• Banned by WADA and most athletic organizations as a prohibited substance

Important: The quality and purity of research-grade peptides varies enormously between suppliers. If using under medical guidance, obtain peptides from licensed compounding pharmacies that provide certificates of analysis (COA) with third-party testing results.

Frequently Asked Questions

How quickly does CJC-1295 work?

The GH pulse occurs within 15-30 minutes of injection (no-DAC version). Subjective effects like improved sleep are often noticed within the first week. Body composition changes typically require 2-3 months of consistent use.

Can I use CJC-1295 without Ipamorelin?

Yes, but the combination is significantly more effective. CJC-1295 alone will increase GH production, but adding Ipamorelin amplifies the release pulse by 2-3x through a complementary mechanism.

Does CJC-1295 suppress natural GH production?

Unlike exogenous GH injections, CJC-1295 works by stimulating your own pituitary to produce GH. This means natural production pathways are preserved. However, prolonged use without cycling may lead to some degree of receptor desensitization.

What is the difference between CJC-1295 and Sermorelin?

Both are GHRH analogs, but CJC-1295 has a much longer half-life and greater potency. Sermorelin (GHRH 1-29) has a half-life of only 10-20 minutes and requires more frequent dosing. CJC-1295’s amino acid substitutions make it resistant to enzymatic degradation.

Can women use CJC-1295?

Yes. CJC-1295 is used by both men and women. Dosing protocols are generally the same, though some physicians recommend starting women at the lower end of the dosage range.

Medical Disclaimer

This article is provided for educational and informational purposes only. CJC-1295 is a research peptide that is not approved by the FDA for human use. The information presented here does not constitute medical advice, and no doctor-patient relationship is implied. Always consult with a qualified healthcare provider before using any peptide or research compound. Self-administration of injectable peptides carries inherent risks including infection, improper dosing, and adverse reactions. Never use research chemicals without proper medical supervision.